5.11
0.44 (9.42%)
| Previous Close | 4.67 |
| Open | 4.65 |
| Volume | 525,171 |
| Avg. Volume (3M) | 247,516 |
| Market Cap | 210,519,584 |
| Price / Sales | 69.43 |
| Price / Book | 50.24 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Operating Margin (TTM) | -3,917.27% |
| Diluted EPS (TTM) | -3.47 |
| Quarterly Revenue Growth (YOY) | -27.40% |
| Total Debt/Equity (MRQ) | 4.68% |
| Current Ratio (MRQ) | 3.67 |
| Operating Cash Flow (TTM) | -67.20 M |
| Levered Free Cash Flow (TTM) | -48.03 M |
| Return on Assets (TTM) | -135.31% |
| Return on Equity (TTM) | -263.65% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Bullish | Mixed |
| Medical Instruments & Supplies (Global) | Bullish | Mixed | |
| Stock | Anteris Technologies Global Cor | Mixed | - |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -1.5 |
| Average | 0.50 |
|
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Value |
| % Held by Insiders | 0.21% |
| % Held by Institutions | 64.12% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| L1 Capital Pty Ltd | 30 Sep 2025 | 6,838,136 |
| Nantahala Capital Management, Llc | 30 Sep 2025 | 1,918,666 |
| Sio Capital Management, Llc | 30 Sep 2025 | 1,772,601 |
| Perceptive Advisors Llc | 30 Sep 2025 | 1,705,130 |
| Ensign Peak Advisors, Inc | 30 Sep 2025 | 1,408,245 |
| Rhenman & Partners Asset Management Ab | 30 Sep 2025 | 1,250,763 |
| Alyeska Investment Group, L.P. | 30 Sep 2025 | 550,000 |
| Eversept Partners, Lp | 30 Sep 2025 | 500,000 |
| Affinity Asset Advisors, Llc | 30 Sep 2025 | 450,000 |
| Northern Trust Corp | 30 Sep 2025 | 255,123 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 17 Nov 2025 | Announcement | Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves |
| 12 Nov 2025 | Announcement | Anteris Announces Results for the Third Quarter of 2025 |
| 03 Nov 2025 | Announcement | FDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”) |
| 28 Oct 2025 | Announcement | Anteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year |
| 27 Oct 2025 | Announcement | Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”) |
| 27 Oct 2025 | Announcement | Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |